EZR and breast carcinoma: Data from our laboratory and other groups have shown that ezrin overexpression in breast cancer cells increases cell scattering and invasion [26, 27], whereas knockdown or mutational inactivation of ezrin reduces cancer cell migration and diminishes the metastatic potential of cancer cells [20, 28–30].